Clinical evaluation of biologically targeted drugs: Obstacles and opportunities Anthony L. BoralScott DessainBruce A. Chabner Review Pages: S3 - S21
Overview of recent topics in clinical pharmacology of anticancer agents Merrill J. Egorin Review Pages: S22 - S30
Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein Yuichi SugiyamaYukio KatoXiao-yan Chu Original Article Pages: S44 - S49
Preclinical approach for identifying drug interactions Tetsuya KamatakiTsuyoshi YokoiYuichi Ando Original Article Pages: S50 - S53
Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models Edward A. SausvilleRichard D. LushSatoshi Kobayashi Original Article Pages: S54 - S59
High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer Martin S. TallmanWilliam J. Gradishar Original Article Pages: S60 - S67
Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in high-risk node-negative breast cancer patients Toru Watanabe Original Article Pages: S68 - S70
Combined-modality treatment for stage IIIa (n2) non-small cell lung cancer: a national cancer institute intergroup study David S. Ettinger Original Article Pages: S71 - S74
National Cancer Institute Clinical Trials Program in Colorectal Cancer Barbara A. ConleyRichard S. KaplanSusan G. Arbuck Original Article Pages: S75 - S79
Clinical trials for advanced gastrointestinal cancers in Japan Yasuhiro Shimada Original Article Pages: S80 - S84
Systems of protocol review, quality assurance, and data audit Raymond B. Weiss Original Article Pages: S88 - S92
Cooperative oncology groups in Japan: Experience from the Japan Adult Leukemia Study Group Ryuzo Ohno Original Article Pages: S93 - S97
European drug development and its impact on national activities: The Dutch example Herbert M. Pinedo Original Article Pages: S98 - S101